Curing malignant carcinomas is a grand ambition in the development of human health. Over
the past decades, targeted therapies have become one of the most successful ways of …

There are several challenges towards the development and clinical use of small molecule
inhibitors, which are currently the main type of targeted therapies towards intracellular …

Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention
over the last 10 years, representing a burgeoning therapeutic approach with the potential to …

Small-molecule targeted protein degraders have in recent years made a great impact on the
strategies of many industry and academic cancer research endeavours. We seek here to …

Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein
degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits …

Proteolysis-targeting chimeric molecules (PROTACs), which attract much more attention
today, may be a potential way to treat cancer. PROTACs are made up of ligands of target …

The PROteolysis TArgeting Chimeras (PROTACs) is an innovative technique for the
selective degradation of target proteins via the ubiquitin–proteasome system. Compared …

Proteolysis targeting chimeras (PROTACs) have been developed to be an effective
technology for targeted protein degradation. Each PROTAC contains three key components …

Proteolysis-targeting chimera (PROTAC) technology represents a novel and promising
modality for targeted protein degradation with transformative implications for the clinical …

Cancer is one of the most common causes of death. So, its lethal effect increases with time.
Near about hundreds of cancers are known in humans. Cancer treatment is done to cure or …